Molecular effects of advanced glycation end products on cell signalling pathways, ageing and pathophysiology

References

• Ulrich P, Cerami A. Protein glycation, diabetes, and aging. Recent Prog Horm Res 2001;56:1–21.
   PubMedGoogle Scholar
• Cho SJ, Roman G, Yeboah F, Konishi Y. The road to advanced glycation end products: a mechanistic perspective. Curr Med Chem 2007;14:1653–1671.
   PubMed Web of Science ®Google Scholar
• Takeuchi M, Yamagishi S. Involvement of toxic AGEs (TAGE) in the pathogenesis of diabetic vascular complications and Alzheimer's disease. J. Alzheimers Dis 2009;16:845–858.
   PubMed Web of Science ®Google Scholar
• Uribarri J, Cai W, Sandu O, Peppa M, Goldberg T, Vlassara H. Diet-derived advanced glycation end products are major contributors to the body's AGE pool and induce inflammation in healthy subjects. Ann N Y Acad Sci 2005; 1043:461–466.
   PubMed Web of Science ®Google Scholar
• Semba RD, Ang A, Talegawkar S, Crasto C, Dalal M, Jardack P, et al. Dietary intake associated with serum versus urinary carboxymethyl-lysine, a major advanced glycation end product, in adults: the Energetics Study. Eur J Clin Nutr 2012;66:3–9.
   PubMed Web of Science ®Google Scholar
• Assar SH, Moloney C, Lima M, Magee R, Ames JM. Determination of Nϵ-(carboxymethyl)lysine in food systems by ultra performance liquid chromatography-mass spectrometry. Amino Acids 2009;36:317–326.
   PubMed Web of Science ®Google Scholar
• Hipkiss AR. Can the beneficial effects of methionine restriction in rats be explained in part by decreased methylglyoxal generation resulting from suppressed carbohydrate metabolism?Biogerontology 2012;13:633–636.
   PubMedGoogle Scholar
• Bryland A, Broman M, Erixon M, Klarin B, Linden T, Friberg H, et al. Infusion fluids contain harmful glucose degradation products. Intensive Care Med 2010;36:1213–1220.
   PubMedGoogle Scholar
• Šebeková K, Somoza V. Dietary advanced glycation endproducts (AGEs) and their health effects – PRO. Mol Nutr Food Res 2007;51:1079–1084.
   PubMed Web of Science ®Google Scholar
• Schmidt AM, Vianna M, Gerlach M, Brett J, Ryan J, Kao J, et al. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem. 1992;267:14987–14997.
   PubMed Web of Science ®Google Scholar
• Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, Arnold B, et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med 2005;83: 876–886.
   PubMed Web of Science ®Google Scholar
• Basta G. Receptor for advanced glycation endproducts and atherosclerosis: from basic mechanisms to clinical implications. Atherosclerosis 2008;196:9–21.
   PubMed Web of Science ®Google Scholar
• Sparvero LJ, Asafu-Adjei D, Kang R, Tang D, Amin N, Im J, et al. RAGE (Receptor for Advanced Glycation Endproducts), RAGE Ligands and their role in Cancer and Inflammation. J Translat Med 2009;7:17.
   PubMed Web of Science ®Google Scholar
• Riehl A, Németh J, Angel P, Hess J. The receptor RAGE: Bridging inflammation and cancer. Cell Commun Signal 2009;7:12.
   PubMed Web of Science ®Google Scholar
• Li J, Schmidt AM. Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J Biol Chem 1997;272:16498–16506.
   PubMed Web of Science ®Google Scholar
• Brett J, Schmidt AM, Yan SD, Zou YS, Weidman E, Pinsky D, et al. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol 1993;143:1699–1712.
   PubMed Web of Science ®Google Scholar
• Sakaguchi M, Murata H, Yamamoto K, Ono T, Sakaguchi Y, Motoyama A, et al. TIRAP, an adaptor protein for TLR2/4, transduces a signal from RAGE phosphorylated upon ligand binding. PLoS One 2011;6:e23132.
   PubMed Web of Science ®Google Scholar
• Hu P, Lai D, Lu P, Gao J, He H. ERK and Akt signaling pathways are involved in advanced glycation end product-induced autophagy in rat vascular smooth muscle cells. Int J Mol Med 2012;29:613–618.
   PubMed Web of Science ®Google Scholar
• Xiang Y, Li Q, Li M, Wang W, Cui C, Zhang J. Ghrelin inhibits AGEs-induced apoptosis in human endothelial cells involving ERK1/2 and PI3K/Akt pathways. Cell Biochem Funct 2011;29:149–155.
   PubMedGoogle Scholar
• Liu Y, Liang C, Liu X, Liao B, Pan X, Ren Y, et al. AGEs increased migration and inflammatory responses of adventitial fibroblasts via RAGE, MAPK and NF-kappaB pathways. Atherosclerosis 2010;208:34–42.
   PubMedGoogle Scholar
• Alikhani M, Maclellan CM, Raptis M, Vora S, Trackman PC, Graves DT. Advanced glycation end products induce apoptosis in fibroblasts through activation of ROS, MAP kinases, and the FOXO1 transcription factor. Am J Physiol Cell Physiol 2007;292:C850–C856.
   PubMedGoogle Scholar
• Yamagishi S, Inagaki Y, Okamoto T, Amano S, Koga K, Takeuchi M, et al. Advanced glycation end products induced apoptosis and overexpression of vascular endothelial growth factor in bovine retinal pericytes. Biochem Biophys Res Commun 2002;290:973–978.
   PubMed Web of Science ®Google Scholar
• Fukami K, Ueda S, Yamagishi S, Kato S, Inagaki Y, Takeuchi M, et al. AGEs activate mesangial TGF-beta-Smad signaling via an angiotensin II type I receptor interaction. Kidney Int. 2004;66:2137–2147.
   PubMed Web of Science ®Google Scholar
• Cai W, Ramdas M, Zhu L, Chen X, Striker GE, Vlassara H. Oral advanced glycation end products (AGEs) promote insulin resistance and diabetes by depleting the antioxidant defenses AGE receptor-1 and sirtuin 1. Proc Natl Acad Sci USA 2012;109:15888–15893.
   PubMed Web of Science ®Google Scholar
• Molinari J, Ruszova E, Velebny V, Robert L. Effect of advanced glycation endproducts on gene expression profiles of human dermal fibroblasts. Biogerontology 2008;9: 177–182.
   Google Scholar
• Bansal S, Siddarth M, Chawla D, Banerjee BD, Madhu SV, Tripathi AK. Advanced glycation end products enhance reactive oxygen and nitrogen species generation in neutrophils in vitro. Mol Cell Biochem 2012;361:289–296.
   PubMed Web of Science ®Google Scholar
• Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier JL.Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 2001;280:E685–E694.
   PubMed Web of Science ®Google Scholar
• Coughlan MT, Thorburn DR, Penfold SA, Laskowski A, Harcourt BE, Sourris KC, et al. RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. J Am Soc Nephrol 2009;20:742–752.
   PubMed Web of Science ®Google Scholar
• Cai W, He JC, Zhu L, Lu C, Vlassara H. Advanced glycation end product (AGE) receptor 1 suppresses cell oxidant stress and activation signaling via EGF receptor. Proc Natl Acad Sci USA 2006;103:13801–13806.
   PubMed Web of Science ®Google Scholar
• Cai W, He JC, Zhu L, Chen X, Striker GE, Vlassara H. AGE-receptor-1 counteracts cellular oxidant stress induced by AGEs via negative regulation of p66shc-dependent FKHRL1 phosphorylation. Am J Physiol Cell Physiol 2008;294:C145–C152.
   PubMed Web of Science ®Google Scholar
• Nagai R, Mera K, Nakajou K, Fujiwara Y, Iwao Y, Imai H, et al. The ligand activity of AGE-proteins to scavenger receptors is dependent on their rate of modification by AGEs. Biochim Biophys Acta 2007;1772:1192–1198.
   PubMedGoogle Scholar
• Pluddemann A, Neyen C, Gordon S. Macrophage scavenger receptors and host-derived ligands. Methods 2007;43: 207–217.
   PubMed Web of Science ®Google Scholar
• Saito A, Takeda T, Hama H, Oyama Y, Hosaka K, Tanuma A, et al. Role of megalin, a proximal tubular endocytic receptor, in the pathogenesis of diabetic and metabolic syndrome-related nephopathies: Protein metabolic overload hypothesis. Nephrology 2005;10:S26–S31.
   Google Scholar
• Rojas A, Delgado-Lopez F, Gonzalez I, Perez-Castro R, Romero J, Rojas I. The receptor for advanced glycation end-products: A complex signaling scenario for a promiscuous receptor. Cell Signal 2013;25:609–614.
   PubMed Web of Science ®Google Scholar
• Ohe K, Watanabe T, Harada S, Munesue S, Yamamoto Y, Yonekura H, Yamamoto H. Regulation of alternative splicing of the receptor for advanced glycation endproducts (RAGE) through G-rich cis-elements and heterogenous nuclear ribonucleoprotein H. J Biochem 2010;147:651–659.
   PubMedGoogle Scholar
• Raucci A, Cugusi S, Antonelli A, Barabino SM, Monti L, Bierhaus A, et al. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J 2008;22:3716–3727.
   PubMed Web of Science ®Google Scholar
• Vazzana N, Santilli F, Cuccurullo C, Davi G. Soluble forms of RAGE in internal medicine. Intern Emerg Med 2009;4:389–401.
   PubMed Web of Science ®Google Scholar
• Lertwittayapon T, Tencomnao T, Santiyanont R. Inhibitory effect of alternatively spliced RAGEv1 on the expression of NF-kB and TNF-α in hepatocellular carcinoma cells. Genet Mol Res 2012;11:1712–1720.
   PubMedGoogle Scholar
• Markaki M, Tavernarakis N. The role of autophagy in genetic pathways influencing ageing. Biogerontology 2011;12: 377–386.
   PubMedGoogle Scholar
• Rattan SI. Biogerontology: from here to where? The Lord Cohen Medal Lecture-2011. Biogerontology 2012;13:83–91.
   PubMed Web of Science ®Google Scholar
• Rattan SI. Increased molecular damage and heterogeneity as the basis of aging. Biol Chem 2008;389:267–272.
   PubMed Web of Science ®Google Scholar
• Trougakos IP, Gonos ES. Chapter 9: Oxidative stress in malignant progression: The role of Clusterin, a sensitive cellular biosensor of free radicals. Adv Cancer Res 2009; 104:171–210.
   PubMed Web of Science ®Google Scholar
• Rattan SI. Synthesis, modification and turnover of proteins during aging. Adv Exp Med Biol 2010;694:1–13.
   PubMedGoogle Scholar
• Hubbard VM, Valdor R, Macian F, Cuervo AM. Selective autophagy in the maintenance of cellular homeostasis in aging organisms. Biogerontology 2012;13:21–35.
   PubMed Web of Science ®Google Scholar
• Li SY, Du M, Dolence EK, Fang CX, Mayer GE, Ceylan-Isik AF, et al. Aging induces cardiac diastolic dysfunction, oxidative stress, accumulation of advanced glycation endproducts and protein modification. Aging Cell 2005;4:57–64.
   PubMed Web of Science ®Google Scholar
• Jacobson J, Lambert AJ, Portero-Otín M, Pamplona R, Magwere T, Miwa S, et al. Biomarkers of aging in Drosophila. Aging Cell 2010;9:466–477.
   PubMed Web of Science ®Google Scholar
• Grimm S, Ernst L, Grötzinger N, Höhn A, Breusing N, Reinheckel T, Grune T. Cathepsin D is one of the major enzymes involved in intracellular degradation of AGE- modified proteins. Free Radic Res 2010;44:1013–1026.
   PubMed Web of Science ®Google Scholar
• Grimm S, Horlacher M, Catalgol B, Hoehn A, Reinheckel T, Grune T. Cathepsins D and L reduce the toxicity of advanced glycation end products. Free Radic Biol Med 2012;52: 1011–1023.
   PubMed Web of Science ®Google Scholar
• Stolzing A, Widmer R, Jung T, Voss P, Grune T. Degradation of glycated bovine serum albumin in microglial cells. Free Radic Biol Med 2006;40:1017–1027.
   PubMed Web of Science ®Google Scholar
• Grimm S, Ott C, Hörlacher M, Weber D, Höhn A, Grune T. Advanced-glycation-end-product-induced formation of immunoproteasomes: involvement of RAGE and Jak2/STAT1. Biochem J 2012;448:127–139.
   PubMed Web of Science ®Google Scholar
• Stratford FL, Chondrogianni N, Trougakos IP, Gonos ES, Rivett AJ. Proteasome response to interferon-gamma is altered in senescent human fibroblasts. FEBS Lett 2006;580:3989–3994.
   PubMed Web of Science ®Google Scholar
• Demir I, Ermiş C, Altunbaş H, Balci MK. Serum HbA1c levels and exercise capacity in diabetic patients. Jpn Heart J 2001;42:607–616.
   PubMedGoogle Scholar
• Vetter SW, Indurthi VSK. Moderate glycation of serum albumin affects folding, stability, and ligand binding. Clin Chim Acta 2011;412:2105–2116.
   PubMed Web of Science ®Google Scholar
• Sell DR, Monnier VM. Molecular basis of arterial stiffening: Role of glycation – A mini-review. Gerontology 2012;58: 227–237.
   PubMed Web of Science ®Google Scholar
• Virella G, Thorpe SR, Alderson NL, Stephan EM, Atchley D, Wagner F, Lopes-Virella MF; DCCT/EDIC Research Group. Autoimmune response to advanced glycosylation end- products of human LDL. J Lipid Res 2003;44:487–493.
   PubMedGoogle Scholar
• Vytásek R, Sedová L, Vilím V. Increased concentration of two different advanced glycation end-products detected by enzyme immunoassays with new monoclonal antibodies in sera of patients with rheumatoid arthritis. BMC Musculoskelet Disord 2010;11:83.
   PubMedGoogle Scholar
• Greenwald SE. Ageing of the conduit arteries. J Pathol 2007;211:157–172.
   PubMedGoogle Scholar
• Ando K, Beppu M, Kikugawa K, Nagai R, Horiuchi S. Membrane proteins of human erythrocytes are modified by advanced glycation end products during aging in the circulation. Biochem Biophys Res Commun 1999;258: 123–127.
   PubMedGoogle Scholar
• Kimura T, Takamatsu J, Ikeda K, Kondo A, Miyakawa T, Horiuchi S. Accumulation of advanced glycation end products of the Maillard reaction with age in human hippocampal neurons. Neurosci Lett 1996;208:53–56.
   PubMed Web of Science ®Google Scholar
• Kumar PA, Kumar MS, Reddy GB. Effect of glycation on a-crystallin structure and chaperone-like function. Biochem J 2007;408:251–258.
   PubMed Web of Science ®Google Scholar
• Kueper T, Grune T, Prahl S, Lenz H, Welge V, Biernoth T, et al. Vimentin is the specific target in skin glycation. Structural prerequisites, functional consequences, and role in skin aging. J Biol Chem 2007;282:23427–23436.
   PubMed Web of Science ®Google Scholar
• Haus JM, Carrithers JA, Trappe SW, Trappe TA. Collagen, cross-linking and advanced glycation end products in aging human skeletal muscle. J Appl Physiol 2007; 103:2068–2076.
   PubMed Web of Science ®Google Scholar
• Semba RD, Bandinelli S, Sun K, Guralnik JM, Ferrucci L. Relationship of an advanced glycation end product, plasma carboxymethyl-lysine, with slow walking speed in older adults: the InCHIANTI study. Eur J Appl Physiol 2010;108:191–195.
   PubMedGoogle Scholar
• Hein G, Wiegand R, Lehmann G, Stein G, Franke S. Advanced glycation end-products pentosidine and Nϵ-carboxymethyllysine are elevated in serum of patients with osteoporosis. Rheumatology 2003;42:1242–1246.
   PubMed Web of Science ®Google Scholar
• Hein GE. Glycation endproducts in osteoporosis—is there a pathophysiologic importance?Clin Chim Acta 2006;371: 32–36.
   PubMed Web of Science ®Google Scholar
• Odetti P, Rossi S, Monacelli F, Poggi A, Cirnigliaro M, Federici M, Federici A. Advanced glycation end-products and bone loss during aging. Ann N Y Acad Sci 2005;1043: 710–717.
   PubMed Web of Science ®Google Scholar
• Tang SY, Zeenath U, Vashishth D. Effects of non-enzymatic glycation on cancellous bone fragility. Bone 2007;40: 1144–1151.
   PubMed Web of Science ®Google Scholar
• Aso Y, Inukai T, Tayama K, Takemura Y. Serum concentrations of advanced glycation endproducts are associated with the development of atherosclerosis as well as diabetic microangiopathy in patients with type 2 diabetes. Acta Diabetol 2000;37:87–92.
   PubMed Web of Science ®Google Scholar
• Bansal S, Chawla D, Siddarth M, Banerjee BD, Madhu SV, Tripathi AK. A study on serum advanced glycation end products and its association with oxidative stress and paraoxonase activity in type 2 diabetic patients with vascular complications. Clin Biochem 2013;46:109–114.
   PubMed Web of Science ®Google Scholar
• Beisswenger PJ, Makita Z, Curphey TJ, Moore LL, Jean S, Brinck-Johnsen T, et al. Formation of immunochemical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes. Diabetes 1995;44:824–829.
   PubMed Web of Science ®Google Scholar
• Kiuchi K, Nejima J, Takano T, Ohta M, Hashimoto H. Increased serum concentrations of advanced glycation end products: a marker of coronary artery disease activity in type 2 diabetic patients. Heart 2001;85:87–91.
   PubMedGoogle Scholar
• Yamagishi S. Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes. Exp Gerontol 2011;46:217–224.
   PubMed Web of Science ®Google Scholar
• Schinzel R, Münch G, Heidland A, Sebekova K. Advanced glycation end products in end-stage renal disease and their removal. Nephron 2001;87:295–303.
   PubMed Web of Science ®Google Scholar
• Sebeková K, Blazícek P, Syrová D, Krivosíková Z, Spustová V, Heidland A, Schinzel R. Circulating advanced glycation end product levels in rats rapidly increase with acute renal failure. Kidney Int Suppl 2001;78:S58–S62.
   Google Scholar
• Stam F, Schalkwijk CG, van Guldener C, ter Wee PM, Stehouwer CDA. Advanced glycation end-product peptides are associated with impaired renal function, but not with biochemical markers of endothelial dysfunction and inflammation in non-diabetic individuals. Nephrol Dial Transplant 2006;21:677–682.
   PubMed Web of Science ®Google Scholar
• Misciagna G, De Michele G, Trevisan M. Non enzymatic glycated proteins in the blood and cardiovascular disease. Curr Pharm Des 2007;13:3688–3695.
   PubMedGoogle Scholar
• Koga M, Kasayama S. Clinical impact of glycated albumin as another glycemic control marker. Endocr J 2010;57: 751–762.
   PubMed Web of Science ®Google Scholar
• Kanauchi M, Tsujimoto N, Hashimoto T. Advanced glycation end products in nondiabetic patients with coronary artery disease. Diabetes Care 2001;24:1620–1623.
   PubMedGoogle Scholar
• McNulty M, Mahmud A, Feely J. Advanced glycation end-products and arterial stiffness in hypertension. Am J Hypertens 2007;20:242–247.
   PubMedGoogle Scholar
• Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 1991;87:432–438.
   PubMed Web of Science ®Google Scholar
• Bucala R, Mitchell R, Arnold K, Innerarity T, Vlassara H, Cerami A. Identification of the major site of apolipoprotein B modification by advanced glycosylation end products blocking uptake by the low density lipoprotein receptor. J Biol Chem 1995;270:10828–10832.
   PubMed Web of Science ®Google Scholar
• Hofnagel O, Luechtenborg B, Weissen-Plenz G, Robenek H. Statins and foam cell formation: impact on LDL oxidation and uptake of oxidized lipoproteins via scavenger receptors. Biochim Biophys Acta 2007;1771:1117–1124.
   PubMedGoogle Scholar
• Shaw SS, Schmidt AM, Banes AK, Wang X, Stern DM, Marrero MB. S100B-RAGE-mediated augmentation of angiotensin II-induced activation of JAK2 in vascular smooth muscle cells is dependent on PLD2. Diabetes 2003;52: 2381–2388.
   PubMed Web of Science ®Google Scholar
• Sakaguchi T, Yan SF, Yan SD, Belov D, Rong LL, Sousa M, et al. Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest 2003;111:959–972.
   PubMed Web of Science ®Google Scholar
• Torreggiani M, Liu H, Wu J, Zheng F, Cai W, Striker G, Vlassara H. Advanced glycation end product receptor-1 transgenic mice are resistant to inflammation, oxidative stress, and post-injury intimal hyperplasia. Am J Pathol 2009;175:1722–1732.
   PubMed Web of Science ®Google Scholar
• Schulz JB, Lindenau J, Seyfried J, Dichgans J. Glutathione, oxidative stress and neurodegeneration. Eur J Biochem 2000;267:4904–4911.
   PubMedGoogle Scholar
• Li J, Liu D, Sun L, Lu Y, Zhang Z. Advanced glycation end products and neurodegenerative diseases: Mechanisms and perspective. J Neurol Sci 2012;317:1–5.
   PubMed Web of Science ®Google Scholar
• Carrano A, Hoozemans JJ, Van der Vies SM, Rozemuller AJ, Van Horssen J, De Vries HJ. Amyloid beta induces oxidative stress-mediated blood-brain barrier changes in capilary amyloid angiopathy. Antioxid Redox Signal 2011;15:1167–1178.
   PubMed Web of Science ®Google Scholar
• Cai Z, Zhao B, Ratka A. Oxidative stress and β-amyloid protein in Alzheimer's Disease. Neuromol Med 2011;13: 223–250.
   PubMed Web of Science ®Google Scholar
• Srikanth V, Maczurek A, Phan T, Steele M, Westcott B, Juskiw D, Münch G. Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease. Neurobiol Aging 2011;32:763–777.
   PubMed Web of Science ®Google Scholar
• Laffont I, Shuvaev VV, Briand O, Lestavel S, Barbier A, Taniguchi N, et al. Early-glycation of apolipoprotein E: Effects on its binding to LDL receptor, scavenger receptor A and heparin sulfate. Biochim Biophys Acta 2002;1583: 99–107.
   PubMedGoogle Scholar
• Candore G, Bulati M, Caruso C, Castiglia L, Colonna- Romano G, Di Bona D, et al. Inflammation, cytokines, immune response, apolipoprotein E, cholesterol, and oxidative stress in Alzheimer disease: Therapeutic implications. Rejuv Res 2010;13:301–313.
   PubMed Web of Science ®Google Scholar
• Seneff S, Wainwright G, Mascitelli L. Nutrition and Alzheimer's disease: The detrimental role of a high carbohydrate diet. Eur J Intern Med 2011;22:134–140.
   PubMed Web of Science ®Google Scholar
• Salminen A, Ojala J, Kauppinen A, Kaarniranta K, Suuronen T. Inflammation in Alzheimer's disease: Amyloid-β oligomers trigger innate immunity defence via pattern recognition receptors. Progress Neurobiol 2009;87:181–194.
   PubMed Web of Science ®Google Scholar
• Cho S. CD36 as a therapeutic target for endothelial dysfunction in stroke. Curr Pharmaceut Des 2012;18:3721–3730.
   PubMed Web of Science ®Google Scholar
• Rojas A, Figueroa H, Morales E. Fueling inflammation at tumor microenvironment: The role of multiligand/rage axis. Carcinogenesis 2010;31:334–341.
   PubMed Web of Science ®Google Scholar
• Sesti F, Tsitsilonis OE, Kotsinas A, Trougakos IP. Oxidative stress-mediated biomolecular damage and inflammation in tumorigenesis. In Vivo 2012;26:395–402.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646–674.
   PubMed Web of Science ®Google Scholar
• Greenhough A, Smartt HJM, Moore AE, Roberts HR, Williams AC, Paraskeva C, Kaidi A. The COX-2/PEG2 pathway: A key role in the hallmarks of cancer and adaptation to the tumor microenvironment. Carcinogenesis 2009;30: 377–386.
   PubMed Web of Science ®Google Scholar
• Takino J, Yamagishi S, Takeuchi M. Glycer-AGEs-RAGE signaling enhances the angiogenic potential of hepatocellular carcinoma by upregulating VEGF expression. World J Gastroenterol 2012;18:1781–1788.
   Google Scholar
• Kang R, Tang D, Schapiro NE, Livesey KM, Farkas A, Loughran P, et al. The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival. Cell Death Differ 2010;17:666–676.
   PubMed Web of Science ®Google Scholar
• Tesarova P, Kalousova M, Jachymova M, Mestek O, Petruzelka L, Zima T. Receptor for advanced glycation end products (RAGE) – soluble form (sRAGE) and gene polymorphism in patients with breast cancer. Cancer Invest 2007;25:720–725.
   PubMed Web of Science ®Google Scholar
• Gebhardt C, Riehl A, Durchdewald M, Nemeth J, Furstenberger G, Muller-Decker K, et al. RAGE signaling sustains inflammation and promotes tumor development. J Exp Med 2008;205:275–285.
   PubMed Web of Science ®Google Scholar
• Turovskaya O, Foell D, Sinha P, Vogl T, Newlin R, Nayak J, et al. RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis 2008;29:2035–2043.
   PubMed Web of Science ®Google Scholar
• Stav D, Bar I, Sandbank J. Usefulness of CDK5RAP3, CCNB2, and RAGE genes for the diagnosis of lung adenocarcinoma. Int J Biol Markers 2007;22:108–113.
   PubMed Web of Science ®Google Scholar
• Sakatani S, Yamada K, Homma C, Munesue S, Yamamoto Y, Yamamoto H, Hirase H. Deletion of RAGE causes hyperactivity and increased sensitivity to auditory stimuli in mice. PLoS One 2009;4:e8309.
   Web of Science ®Google Scholar
• Kodavanti UP, Thomas R, Ledbetter AD, Schaldweiler MC, Shannahan JH, Wallenborn JG, et al. Vascular and cardiac impairment in rats inhaling ozone and diesel exhaust particles. Environm Health Perspect 2011;119:312–318.
   PubMed Web of Science ®Google Scholar
• Giordano D. Tobacco smoke is a source of advanced glycation end products (AGEs): possible role in the accelerated vascular disease of smokers. J Invest Med 1996;44:200a.
   PubMedGoogle Scholar
• Campos C, Guzmán R, López-Fernández E, Casado A. Urinary biomarkers of oxidative/nitrosative stress in healthy smokers. Inh Toxicol 2011;23:148–156.
   PubMed Web of Science ®Google Scholar
• Tessier FJ, Birlouez-Aragon I. Health effects of dietary Maillard reaction products: The results of ICARE and other studies. Amino Acids 2012;42:1119–1131.
   PubMed Web of Science ®Google Scholar
• Koschinsky T, He CJ, Mitsuhashi T, Bucala R, Liu C, Buenting C, et al. Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc. Natl Acad. Sci. USA 1997;94:6474–6479.
   PubMed Web of Science ®Google Scholar
• Šebeková K, Saavedra G, Zumpe C, Somoza V, Klenovicsová K, Birlouez-Aragon I. Plasma concentration and urinary excretion of Ne-(carboxymethyl)lysine in breast milk- and formula-fed infants. Ann N Y Acad Sci. 2008;1126:177–180.
   PubMed Web of Science ®Google Scholar
• Vlassara H, Cai W, Crandall J, Goldberg T, Oberstein R, Dardaine V, et al. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci USA 2002;99:15596–15601.
   PubMed Web of Science ®Google Scholar
• Cai W, He JC, Zhu L, Peppa M, Lu C, Uribarri J, Vlassara H. High levels of dietary advanced glycation end products transform low-density lipoprotein into a potent redox- sensitive mitogen-activated protein kinase stimulant in diabetic patients. Circulation 2004;110:285–291.
   PubMed Web of Science ®Google Scholar
• Yang CW, Vlassara H, Peten EP, He CJ, Striker GE, Striker LJ. Advanced glycation end products upregulate gene expression found in diabetic glomerular disease. Proc Natl Acad Sci USA 1994;91:9436–9440.
   PubMed Web of Science ®Google Scholar
• Vlassara H, Striker LJ, Teichberg S, Fuh H, Li YM, Steffes M. 1994. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci USA 1994;91:11704–11708.
   PubMed Web of Science ®Google Scholar
• Zheng F, He C, Cai W, Hattori M, Steffes M, Vlassara H. Prevention of diabetic nephropathy in mice by a diet low in glycoxidation products. Diab Metab Res Rev 2002;18: 224–237.
   PubMed Web of Science ®Google Scholar
• Lin RY, Choudhury RP, Cai W, Lu M, Fallon JT, Fisher EA, Vlassara H. Dietary glycotoxins promote diabetic atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis 2003;168:213–220.
   PubMed Web of Science ®Google Scholar
• Sandu O, Song K, Cai W, Zheng F, Uribarri J, Vlassara H. Insulin resistance and type 2 diabetes in high-fat-fed mice are linked to high glycotoxin intake. Diabetes 2005; 54:2314–2319.
   PubMedGoogle Scholar
• Susic D. Cross-link breakers as a new therapeutic approach to cardiovascular disease. Biochem Soc Trans 2007;35: 853–856.
   PubMedGoogle Scholar
• Ueda S, Yamagishi S, Takeuchi M, Kohno K, Shibata R, Matsumoto Y, et al. Oral adsorbent AST-120 decreases serum levels of AGEs in patients with chronic renal failure. Mol Med 2006;12:180–184.
   PubMed Web of Science ®Google Scholar
• Vlassara H, Li YM, Imani F, Wojciechowicz D, Yang Z, Liu FT, Cerami A. Identification of galectin-3 as a high- affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex. Mol Med 1995;1:634–646.
   PubMed Web of Science ®Google Scholar
• Iacobini C, Menini S, Oddi G, Ricci C, Amadio L, Pricci F, et al. Galectin-3/AGE-receptor 3 knockout mice show accelerated AGE-induced glomerular injury: evidence for a protective role of galectin-3 as an AGE receptor. FASEB J 2004;18:1773–1775.
   PubMedGoogle Scholar
• Iacobini C, Oddi G, Menini S, Amadio L, Ricci C, Di Pippo C, et al. Development of age-dependent glomerular lesions in galectin-3/AGE-receptor-3 knockout mice. Am J Physiol Renal Physiol 2005;289:F611–F621.
   Google Scholar
• Bolton WK, Cattran DC, Williams ME, Adler SG, Appel GB, Cartwright K, et al. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol 2004;24:32–40.
   PubMed Web of Science ®Google Scholar
• Coughlan MT, Forbes JM, Cooper ME. Role of the AGE crosslink breaker, alagebrium, as a renoprotective agent in diabetes. Kidney Int Suppl 2007;106:S54–S60.
   Google Scholar
• Padival S, Nagaraj RH. Pyridoxamine inhibits maillard reactions in diabetic rat lenses. Ophthalmic Res 2006;38: 294–302.
   PubMedGoogle Scholar
• Adrover M, Vilanova B, Frau J, Muñoz F, Donoso J. The pyridoxamine action on Amadori compounds: A reexamination of its scavenging capacity and chelating effect. Bioorg Med Chem 2008;16:5557–5569.
   PubMed Web of Science ®Google Scholar
• Waanders F, van den Berg E, Nagai R, van Veen I, Navis G, van Goor H. Renoprotective effects of the AGE-inhibitor pyridoxamine in experimental chronic allograft nephropathy in rats. Nephrol Dial Transplant. 2008;23:518–524.
   PubMedGoogle Scholar
• Motomura K, Fujiwara Y, Kiyota N, Tsurushima K, Takeya M, Nohara T, et al. Astragalosides isolated from the root of astragalus radix inhibit the formation of advanced glycation end products. J Agric Food Chem 2009;57:7666–7672.
   PubMed Web of Science ®Google Scholar
• Karachalias N, Babaei-Jadidi R, Rabbani N, Thornalley PJ. Increased protein damage in renal glomeruli, retina, nerve, plasma and urine and its prevention by thiamine and benfotiamine therapy in a rat model of diabetes. Diabetologia 2010;53:1506–1516.
   PubMedGoogle Scholar
• Stirban A, Negrean M, Stratmann B, Gawlowski T, Horstmann T, Götting C, et al. Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes. Diabetes Care 2006;29:2064–2071.
   PubMed Web of Science ®Google Scholar
• Alkhalaf A, Kleefstra N, Groenier KH, Bilo HJ, Gans RO, Heeringa P, et al. Effect of benfotiamine on advanced glycation endproducts and markers of endothelial dysfunction and inflammation in diabetic nephropathy. PLoS One 2012;7:e40427.
   Google Scholar
• Nagai R, Shirakawa JI, Ohno RI, Moroishi N, Nagai M. Inhibition of AGEs formation by natural products. Amino Acids 2013; [Epub ahead of print]
   Google Scholar
• Reiniger N, Lau K, McCalla D, Eby B, Cheng B, Lu Y, et al. Deletion of the receptor for advanced glycation end products reduces glomerulosclerosis and preserves renal function in the diabetic OVE26 mouse. Diabetes 2010; 59:2043–2054.
   PubMed Web of Science ®Google Scholar
• Deane R, Singh I, Sagare AP, Bell RD, Ross NT, LaRue B, et al. A multimodal RAGE-specific inhibitor reduces amyloid β-mediated brain disorder in a mouse model of Alzheimer disease. J Clin Invest 2012;122:1377–1392.
   PubMed Web of Science ®Google Scholar
• Yamagishi S, Matsui T, Nakamura K. Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes. Curr Drug Targets 2007;8:1138–1143.
   PubMed Web of Science ®Google Scholar
• Steele M, Stuchbury G, Münch G. The molecular basis of the prevention of Alzeimer's disease through healthy nutrition. Exp Gerontol 2007;42:28–36.
   PubMed Web of Science ®Google Scholar